Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta Therapeutics Inc.

www.sarepta.com

Latest From Sarepta Therapeutics Inc.

OptumRx WatchList Includes Rare Disease Drugs, Potential Price Disruptors

Pharmacy benefit manager’s new pipeline report offers insight into upcoming drugs of concern to payers.

Commercial Pharmacy Benefit Management

Solid Biosciences’ DMD Gene Therapy Undermined By Safety Wobbles

Another setback for the novel therapy leaves rivals Sarepta and Pfizer in a stronger position in a potentially highly rewarding market.

Clinical Trials Gene Therapy

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Deals Financing

Dyne Launches With $50m For Antibody Conjugates That Deliver Oligonucleotides To Muscles

The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • AVI BioPharma Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sarepta Therapeutics Inc.
  • Senior Management
  • Douglas Ingram, Pres. & CEO
    Sandesh Mahatme, EVP, CFO & CBO
    Bo Cumbo, SVP, Chief Commercial Officer
    Gilmore O'Neill, SVP, R&D & CMO
  • Contact Info
  • Sarepta Therapeutics Inc.
    Phone: (617) 274-4000
    215 First St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register